Brought to you by 
Novartis gets rights to Arakis and Vectura's AD237
28 May 2019
Executive Summary
Novartis AG has been granted worldwide development and market rights to Arakis Ltd.'s (oncology and inflammatory diseases) and Vectura Ltd.'s (formulation technologies) AD237 (glycopyrronium bromide), a drug candidate in Phase II studies for chronic obstructive pulmonary disease (COPD).
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets rights to Arakis and Vectura's AD237
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice